CORRECTING AND REPLACING: Hemispherx Biopharma Reports

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
124
CORRECTING AND REPLACING: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

ORLANDO, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by Hemispherx Biopharma, Inc. (NYSE American:HEB) with the same headline, the net loss from operations was incorrect in the fourth paragraph. It should say $0.07 per share, not $0.70 per share. The corrected release follows.

Hemispherx Biopharma, Inc. (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders through the development of its immunology products Ampligen® and Alferon®, today announced its financial results for the first quarter ended March 31, 2018.

“We made significant progress in the quarter that just ended, including significant improvements to our balance sheet, the production of the equivalent of more than 8,500 vials of Ampligen at our contract fill and finish manufacturer, the expansion of our Ampligen supply agreements for early access programs in Canada and Europe under the management of myTomorrows, and the continuation of our plans to start advanced clinical trials of Ampligen as a single agent and a combination immuno-oncology therapy,” said Thomas K. Equels, Hemispherx’s chief executive officer.

“During the quarter we added to our cash by booking Ampligen sales, the sale/leaseback of our manufacturing facility, the sale of non-strategic real estate, and the exercise of warrants and the sale of common stock,” he continued. “We believe that this will enable us to meet the current and anticipated needs of our commercial channels and clinical study programs, as we work with the FDA to identify a path toward approval for Ampligen for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” 

First Quarter 2018 Financial Highlights As of March 31, 2018, Hemispherx had $4.6 million in cash and cash equivalents, compared to $2.1 million at December 31, 2017. Cash used in operations was $2.5 million for the three months ended March 31, 2018, compared to $3.0 million in the same quarter in 2017. The net loss from operations was $2.7 million, or $0.07 per share, for the first quarter of 2018, compared to a net loss of $2.8 million, or $0.11 per share, for the first quarter of 2017.

A bout Hemispherx Biopharma Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for the treatment of serious and debilitating disorders. Hemispherx's flagship products include the FDA-approved drug Alferon N Injection® and the Argentina-approved drug rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is a double-stranded RNA being developed for globally important diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Because rintatolimod has not been designated safe and effective by the FDA for general use, it is legally available in the United States only through clinical trials. However, Ampligen® has been approved in Argentina for ME/CFS and the company is working toward legal access in other countries where early access programs exist for serious diseases with unmet medical needs, such as ME/CFS. Ampligen® is the only therapy approved anywhere in the world for ME/CFS. An Ampligen® Early Access Program (EAP) approval has also been obtained for therapeutic use in the Netherlands for pancreatic cancer.

Cautionary Statement Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contact Hemispherx Biopharma Phone Number: 800-778-4042 Email: IR@hemispherx.net

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 34

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 112

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 268

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Crypto: Brian Armstrong on Innovative Payment Solutions

Updated Category News Views 292

Coinbase's Vision for Payments in the Crypto World Brian Armstrong, the CEO of Coinbase Global Inc. (NASDAQ: COIN), is optimistic about the role of payments as a transformative use case within the cryptocurrency landscape. In a recent discussion, he articulated how he believes this sector will significantly evolve, particularly in terms of integrating stablecoins into...

Continue Reading
Veeva Basics Empowering Biotechs to Enhance Efficiency and Growth

Updated Category News Views 185

Veeva Basics Revolutionizes Biotech Operations In today's fast-paced biotech landscape, efficient operations are crucial. Veeva Systems (NYSE: VEEV) has introduced Veeva Basics, a solution now adopted by over 100 emerging biotechs. With this innovative approach, these companies can simplify and standardize their operations, allowing them to focus on what truly matters:...

Continue Reading
Exploring the Rise of Small-Cap Stocks: A 2024 Overview

Updated Category News Views 613

Small-Cap Stocks Lead 2024 Gains In the vibrant market of 2024, small-cap stocks have shined brighter than ever, showcasing remarkable performance that has left traditional blue-chip stocks in their wake. While larger, well-known companies often dominate discussions, smaller firms are making headlines with exhilarating returns. Remarkable Returns in the Market This year,...

Continue Reading
Ridge Street Capital Signs Significant Growth in Lending Sector

Updated Category News Views 206

Ridge Street Capital's Impressive Growth in Investment Lending Ridge Street Capital, a dynamic private lending firm, is celebrating a remarkable achievement in its operation, reporting over 150% growth from one year to the next. This impressive advancement marks the firm as a key player in investment property financing, primarily due to its tailored approach and...

Continue Reading
Kuehn Law Advocates for Sarepta Therapeutics Shareholders

Updated Category News Views 153

Kuehn Law Advocates for Sarepta Therapeutics Shareholders Kuehn Law, PLLC, a law firm dedicated to shareholder litigation, is reaching out to investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) regarding pressing concerns that have surfaced about the company's internal practices. Recent investigations suggest that certain officers and directors possibly did not uphold...

Continue Reading